心脏手术后难治性自身免疫性肝素诱导的血小板减少症
本文报告一例既往有自身免疫性肝素诱导的血小板减少症(aHIT)病史的患者,在心脏手术中再次暴露于肝素后复发aHIT并发生肺栓塞。替代抗凝药及大剂量静脉免疫球蛋白均无效,仅多次治疗性血浆置换恢复血小板计数并阻止血栓进展;体外抗PF4介导血栓模型准确预测临床结局,且致血栓能力主要由非肝素依赖性抗PF4抗体引起。
要点
- 既往aHIT患者心脏手术再暴露肝素可复发aHIT并发生肺栓塞。
- 替代抗凝药及大剂量静脉免疫球蛋白无效,多次治疗性血浆置换恢复血小板并阻止血栓进展。
- 体外抗PF4介导血栓模型准确预测临床结局,致血栓主要源于非肝素依赖性抗PF4抗体。
核心结论
- 首次描述复发性aHIT,并提供转化证据表明致病性非肝素依赖性抗PF4抗体可被治疗性血浆置换特异性靶向,强调其在难治性aHIT中的临床应用。
研究设计与样本
- 病例报告:一例既往有aHIT病史的患者在心脏手术中再次暴露于肝素。
主要发现
- 再次暴露肝素后复发aHIT并发生肺栓塞。
- 替代抗凝药及大剂量静脉免疫球蛋白无效。
- 仅多次治疗性血浆置换恢复血小板计数并阻止进一步血栓进展。
- 体外抗PF4介导血栓模型准确预测临床结局。
- 致血栓形成能力主要由非肝素依赖性抗PF4抗体引起。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune heparin-induced thrombocytopenia (aHIT) is a severe subtype of heparin-induced thrombocytopenia characterized by persistent thrombocytopenia and prothrombotic condition, even though anticoagulation with heparin has been discontinued. Here, we report on a patient with a previous history of aHIT where reexposure to heparin during cardiac surgery resulted in recurrent aHIT with pulmonary embolism. Alternative anticoagulants, as well as high-dose intravenous immunoglobulin, were ineffective, and only multiple cycles of therapeutic plasma exchange restored platelet counts and prevented further thrombosis progression. The therapy was guided by an ex vivo model of antiplatelet factor 4 (PF4)-mediated thrombosis that showed accurate performance in predicting the clinical outcome. Most importantly, the ability to induce thrombus formation was mainly caused by anti-PF4 (heparin-independent) antibodies. Our paper provides the first description of recurrent aHIT with translational evidence that pathogenic heparin-independent anti-PF4 antibodies can be specifically targeted by therapeutic plasma exchange, emphasizing the clinical use in refractory cases of aHIT.
引用
- Zlamal J, Bohnert BN, Althaus K, et al. Refractory autoimmune heparin-induced thrombocytopenia following cardiac surgery. J Thromb Haemost. 2025. PMID: 40158808. doi:10.1016/j.jtha.2025.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。